Advanced Filters
noise
Found 64,756 clinical trials
M Maud Boreel, Msc

The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease

Ménière's disease is an inner ear disorder in which patients suffer from attacks of vertigo, tinnitus and hearing loss. To date, it is unclear what the best treatment for this condition is. Giving injections in the inner ear with the adrenal cortical hormone methylprednisolone is a treatment that is already …

18 - 100 years of age All Phase 3
C Carla Sharp, Ph.D.

MISC-IPV: a Community-Based Intervention for Children Traumatized by Intimate Partner Violence

This study adapts and evaluates preliminary outcomes of the Mediational Intervention for Sensitizing Caregivers (MISC) for women and children of color who have survived domestic violence.

7 - 65 years of age All Phase N/A
J John Robb

Genetic Basis of Melanocytic Nevi

The objective of this protocol is to further elucidate the genetic mutations that drive melanocytic nevi (benign melanocytic neoplasms, moles). This will be performed by whole genome, whole exome, or targeted sequencing of de-identified specimens. Herein, the investigators plan to isolate DNA from de-identified skin biopsy specimens and blood samples: …

18 years of age All Phase N/A
T Tamkin Shahraki, MD

Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in …

18 years of age All Phase N/A
S Se-Hoon Lee, M.D., Ph.D.

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.

30 - 75 years of age All Phase 2
J Jeannine M Haller, RN, CCRP

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

18 - 65 years of age All Phase 2
H Humberto Martinez, COT

OCT in Fuchs' Dystrophy

This is an observational study using optical coherence tomography (OCT) technology to quantify corneal edema in Fuchs' endothelial dystrophy and predict refractive shift from resolving corneal edema after surgical treatments.

18 years of age All Phase N/A
D Dai Chihara, M D

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

18 years of age All Phase 2
E Elizabeth Klerman, MD PhD

Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms

The goal of this clinical trial is to learn how the pupil responds to different light stimuli and how that relates to sleep and daily rhythms in healthy people of different ages. The main questions it aims to answer are: Does the eye's pupil response to light stimuli differ by …

18 - 85 years of age All Phase N/A
L Lisa Vandermeer, MSc

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to …

18 years of age All Phase 4

Simplify language using AI